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Background: The issue of a potential association between thyroid conditions/hormones and breast cancer
has been studied extensively during the last decades but the results have been inconclusive and almost no
studies have investigated breast cancer aggressiveness. We have previously found a positive association
between prospectively measured levels of triiodothyronine (T3) and breast cancer incidence as well as breast
cancer mortality. We now investigated prediagnostic T3 levels in relation to specific prognostic factors in
breast cancer.
Methods: The Malmö Preventive Project is a population-based prospective cohort including 2185 women in
whom T3 levels were measured at baseline. That is, total T3 levels were measured before a potential diagnosis
of breast cancer. Mean follow-up was 23.3 years and 149 women in the study population were diagnosed with
invasive breast cancer. Tumours were classified according to selected prognostic factors of breast cancer; i.e.
grade, tumour size, lymph node metastasis, and hormonal receptor status. T3 was handled both as tertiles and
as a continuous variable. A Cox’s proportional hazards analysis yielded hazard ratios with 95% confidence
intervals. All analyses were also restricted to postmenopausal women.
Results: Overall there was a statistically significant association between T3 and “all” breast cancers. The
adjusted Hazard Ratio (HR) in the third tertile, as compared to the first, was (1.61:1.07-2.43). There was a
statistically significant positive association between the third T3 tertile and large tumours, i.e. > 20 mm,
(3.17:1.20-8.36) and the occurrence of lymph node metastases, (4.53:1.60-12.83). Other prognostic factors
positively associated with T3 were negative oestrogen receptor (ER) status, (3.52:1.32-9.41) and negative
progesterone receptor (PGR) status, (3.52:1.42-8.75). The analyses of T3 as a continuous variable and analysis
restricted to postmenopausal women, confirmed the results but also showed an association with smaller
tumours and in postmenopausal women a contemporary association with negative lymph nodes.
Conclusions: This prospective study of serum T3 levels in relation to breast cancer aggressiveness is the first
of its kind. We found statistically significant positive associations between higher prediagnostic T3 levels
and larger tumours, occurrence of lymph node metastases, and negative ER and PGR status.
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Thyroid disorders and breast cancer are both common
in postmenopausal women, and an association between
these conditions would have a large clinical impact. The
issue of a potential association between thyroid conditions/
hormones and breast cancer risk has been studied exten-
sively during the last decades but the results have so far
been inconclusive [1-3]. Interpretation of previous studies
is difficult as almost all have been cross-sectional. This is a
major problem when measuring thyroid hormones in
breast cancer patients as the disease per se, as well as its
treatment, may affect hormonal levels.
In order to investigate whether there is an association
between thyroid hormones and breast cancer, the most
relevant design would be to use pre-diagnostically
measured hormonal levels.
The overwhelming part of previous studies on thyroid
hormones and breast cancer, has investigated the risk of
breast cancer. Another aspect is clinical outcome, e.g.
survival. To our knowledge, only two previous studies,
including 84 and 47 patients respectively, have investi-
gated thyroid hormones in relation to survival following
breast cancer, but they found no clear association [4,5].
The literature on thyroid disorders and breast cancer
aggressiveness or prognostic factors is also very scarce.
One study has shown that thyroid autoimmunity in rela-
tion to breast cancer aggressiveness is associated with a
lower frequency of distant metastasis [6]. Another cross-
sectional study on thyroid conditions and breast cancer
aggressiveness found no relation to the histopathological
grade but a higher frequency of metastatic lymph nodes
and vascular invasion in patients with thyroid pathology
[7]. However, an early cross-sectional study by Lemaire
et al. showed no relation between thyroid function and
TNM stage of breast cancer [8].
In two recent prospective studies, we found a positive
association between prediagnostic thyroid hormone
levels and the risk of developing breast cancer [9,10].
Furthermore, we have also – based on the same cohort
as one of these studies – shown a positive association
between prediagnostic triiodothyronine (T3) levels and
breast cancer mortality [11]. Total T3 and not T4 was
chosen as the exposure in that and the present study,
since at baseline, when blood samples for thyroid status
were collected, only total T3 and TSH were analysed.
A question that remains to be answered is if this high
mortality is related to a higher incidence or more aggres-
sive forms of breast cancer.
The aim of the present study was to investigate the as-
sociation between prediagnostic T3 levels and prognostic
factors related to breast cancer aggressiveness; i.e.
tumour size, grade, lymph node metastases, and hor-
monal receptor status.This was studied in a prospective
cohort of 2185 women, out of whom 149 were diagnosedwith invasive breast cancer during a follow-up of at least
18 years.
Methods
The malmö preventive project
Originally, 10 902 women participated in the Malmö
Preventive Project. The project was established in 1974
when residents in Malmö, a city in southern Sweden,
were invited to participate in a health survey. Entire birth
cohorts, men and women, were examined until 1992 when
the department closed. Approximately 70% of invited
subjects participated [12].
All women answered a questionnaire concerning
sociodemographic information, lifestyle habits, and med-
ical history. Questions on reproductive factors, i.e. oral
contraceptives (OC) and menopausal status, were included
in women screened from April 1983 and onward. BMI
(kg/m2) was assessed at baseline examination [12]. A
subject was considered to have a history of goitre if the
question ‘have you been treated for goitre’ was answered
with ‘yes’. The baseline questionnaire included no ques-
tions on specific type of previous thyroid disorders or
previous medications.
The present study was approved by the ethical committee
at Lund University: Dnr 652/2005 and Dnr 501/2006.
All former participants were informed about the present
study by newspaper as required by the local ethical com-
mittee. All participants were offered to be excluded from
the present study if they wished so, by contacting the
authors via an enclosed telephone number. None of the
participants took contact.
T3 analysis
Blood samples were taken after an overnight fast with the
patient in the supine position. The serum samples were
analysed at baseline for total T3 and TSH in women born
in 1928 and 1941 and examined in 1983 and 1984. In
women born in 1935 (examined from 1990 to 1992), total
T3 was measured in a subset of all women, i.e. those with
pathological TSH values, a history of thyroid disease, or
those with an enlarged thyroid gland at examination. In
addition to this, the attending physician could also decide
to analyse T3 [5]. Total T3 was measured by a double
antibody RIA (reference interval 0.9–3.2 mmol/l) [13].
Only six women had a value above the upper reference
limit.
Study cohort and follow-up
Among 10 902 women, reproductive data including
menopausal status had been assessed in 8051 subjects.
T3 had been measured in 2383 women (1161 born in
1928, 907 born in 1941, and 315 born in 1935). Women
with prevalent breast cancer (n = 35), goitre (n = 167),
or both (n = 4) were identified and excluded from this
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women with information on T3 and without breast cancer
at baseline or a record of goitre. Tumour endpoints were
retrieved by record linkage with the Swedish Cancer
Registry and the Southern Swedish Regional Tumour
Registry until the end of follow up, the 31 December
2010. Following baseline examination, 149 women in the
study population were diagnosed with invasive breast
cancer during a mean follow-up of 23.3 years (stan-
dard deviation 6.2) and total follow-up included 50 807
person years. Information on vital status was retrieved
from the Swedish Cause-of-Death Registry up until 31
December 2010.
Tumour grading and staging
The evaluation of tumour samples diagnosed until
December 2004, was originally performed as part of a
previous study [14]. The tumour samples were re-
evaluated by three senior pathologists. Histologic grade
was assessed according to the Nottingham classification
(NHG) as previously described [15]. Information on
tumour characteristics in breast cancers diagnosed from
January 2005 until December 2010 was obtained from
the original pathology reports. Lymph node status and
tumour size, were obtained from pathology reports. Size
was divided into two groups with a cut-off at 20 mm,
the size that discriminates T1 from T2 tumours in the
TNM classification [16].
Receptor status
Information on oestrogen receptor (ER) and progester-
one receptor (PGR) status in tumours diagnosed before
the 30th of April 1997 was obtained by re-examination
of collected tumour tissue by two senior pathologists
using an immunohistochemical (IHC) method [17]. For
tumours in the present study diagnosed following this
date, information on receptor status was obtained from
the original pathology reports as the IHC method had
then been implemented into clinical practice. In 18
cases, information on receptor status was missing. These
tumour samples were retrieved and examined, using the
same method as above, by a senior pathologist (LB).
Receptor staining in more than 10% of the tumour cells
was regarded as positive.
Statistical methods
Distribution of established and potential risk factors for
breast cancer was investigated in breast cancer cases and
the rest of the cohort. Tertile cut-points for T3 were
based on the distribution among all women in the study
population. Hazard ratios (HR), with 95% confidence
intervals (CI), were calculated using Cox’s proportional
hazards analysis. The assumption of proportional hazards
was met as tested by log-minus log curves.For all the analysis a P value < 0.05 was considered as
statistically significant.
Analyses were subsequently adjusted for age at base-
line. The limited number of breast cancer cases in each
subgroup did not allow inclusion of all covariates in the
same model, but in relation to invasive breast cancer,
age and one additional factor at a time were included in
the same model. In this way, OC affected the HRs most,
with an increase of the HR by a value of 0.14, whereas
the other covariates lead to barley any change of the
HRs (0.00-0.02). Hence, the only adjusted model used
for all different sub groups was the one including age at
baseline and OC.
All the analyses were repeated with T3 as a continuous
variable. T3 was not normally distributed (p < 0.001 using
a one sample Kolmogorov–Smirnov test), but to give esti-
mates more readily interpretable, the original T3 values
were used to obtain HRs. However, T3 values were also
transformed using the natural logarithm in order to con-
firm whether the associations were statistically significant
or not. The analysis with continuous T3 was stratified
according to menopausal status. In a sensitivity analysis,
all analyses were repeated excluding cases with diagnosis
of breast cancer within two years following baseline.
Results
Invasive cases had less often had children than women
in the rest of the cohort. Never smoking, being married,
and abstaining alcohol was also more common in invasive
cases. All other potential and established risk factors were
evenly distributed in invasive cases and the rest of the
cohort (Table 1). The distribution of potential and estab-
lished risk factors according to serum level of T3 are pre-
sented in Table 2.
All breast tumours
The third T3 tertile had a statistically significant associ-
ation with “all” breast cancers in the analysis adjusted
for age and OC (Table 3). This was also confirmed in
the continuous analysis (Table 4), and the association
was even stronger in postmenopausal women (Table 5).
All of the results regarding “all” tumours, and also re-
garding all other analyses below, were similar when cases
diagnosed during the first two years following baseline
were excluded (data not shown).
Grade
Concerning NHG I tumours, there was no statistically
significant association with T3 in the tertile or continuous
analysis (Tables 3 and 4). Likewise, no association was
seen after stratification for menopause status (Table 5).
There was a statistically significant association between
the highest T3 tertile and NHG II tumours. However in
this subgroup the amount of cases was higher rendering
Table 1 Distribution of established and potential risk factors for breast cancer in women with breast cancer and the
rest of cohort
Factor CIS n = 21 Invasive n = 149 Rest of cohort* n = 2015 All n = 2185
(column percent; mean (SD) in italics)
Age at baseline (years) 48.1(6.7) 49.9(6.5) 50.5(6.4) 50.4(6.4)
Age <50 57.1 43.6 39.2 39.7
Age >50 42.9 56.4 60.8 60.3
BMI (kg/m2) 25.1(5.8) 24.7(4.4) 24.2(4.1) 24.3(4.1)
BMI <20 9.5 7.4 10.3 10.1
BMI ≥20 < 25 52.4 51.7 55.0 54.7
BMI ≥25 < 30 23.8 29.5 25.2 25.5
BMI ≥30 14.3 11.4 9.5 9.7
Age at menarche
<12 years 9.5 14.1 12.6 12.6
>12 years 90.5 84.6 86.7 86.6
Missing - 1.3 0.7 0.7
Oral contraceptives
Yes 9.5 6.0 7.7 7.6
No 90.5 93.3 91.9 92.0
Missing - 0.7 0.3 0.4
Postmenopausal
Yes 47.6 56.4 61.0 60.5
No 52.6 43.6 39.0 39.5
Children
Yes 76.2 77.9 83.1 82.6
No 23.8 21.5 16.7 17.1
Missing - 0.7 0.2 0.3
HRT in postmenopausal
Yes 10 11.9 15.7 15.4
No 90 88.1 84.2 84.5
Missing - - 0.1 0.1
Smoking status
Never 42.9 51.7 46.3 46.6
Ex 23.8 20.1 19.0 19.1
Current 33.3 27.5 34.5 34.0
Missing - 0.7 0.3 0.3
Married
Yes 42.9 60.4 52.4 52.9
No 47.6 31.5 42.0 41.3
Missing 9.5 8.1 5.6 5.8
Alcohol consumption
None 9.5 20.8 14.7 15.1
Less than every week 57.1 53.7 60.2 59.7
Every week 33.3 24.8 24.6 24.7
Missing - 0.7 0.5 0.5
Education
Tosovic et al. BMC Cancer 2014, 14:536 Page 4 of 10
http://www.biomedcentral.com/1471-2407/14/536
Table 1 Distribution of established and potential risk factors for breast cancer in women with breast cancer and the
rest of cohort (Continued)
≤12 years 76.2 79.1 81.6 81.4
>12 years 23.8 16.9 14.4 14.6
Missing - 4.0 4.0 4.0
*Including one case where information on CIS or invasive status was not known.
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significance concerning NHG II. This association was
even stronger when adjusted for age and age and OC
(Table 3). The association was also confirmed by the
continuous analysis (Table 4), and even stronger among
postmenopausal women (Table 5). There was no statisti-
cally significant association in any of the analyses concern-
ing NHG III tumours.
Tumours size
There was no association between T3 and tumours with
a size ≤ 20 mm in the tertile analysis (Table 3). However,
in the adjusted continuous analysis, there was a statis-
tically significant positive association (Table 4) which
was even more pronounced in postmenopausal women
(Table 5). Positive, statistically significant associations
were found in the T3 tertile analyses, for tumours with
a size > 20 mm (Table 3). This association was weaker
in the continuous analysis and statistically significant
only in the analysis adjusted for age (Table 4). After
stratification for menopausal status the association was
lost (Table 5).
To summarize, the tertile analysis showed a high risk
for large tumours ( >20 mm), but not for small tumours.
The continuous analysis was only statistically significant
for small tumours (even if the point estimate for large
tumours was actually slightly higher). In postmenopausal
women, there was still a high risk of large tumours (HR:
1.83), but it was not statistically significant and the risk
for small tumours was clearly higher (HR: 3.33).
Nodal status
There was a statistically significant positive association
in a dose response pattern between T3 tertiles and the
risk of a positive nodal status (Table 3). The association
grew stronger when adjusted and was confirmed by the
continuous analysis (Table 4) and in the analysis includ-
ing only postmenopausal women (Table 5). Concerning
negative nodal status, there was no association with T3
levels in the tertile or continuous analyses (Tables 3
and 4), but in the postmenopausal women, there was a
positive statistically significant association that grew stron-
ger after adjustment (Table 5). Comparing the risk of dif-
ferent nodal status in postmenopausal women, the risk
was higher for node positive tumours (HR: 3.37) as com-
pared to node negative tumours (HR: 2.12).ER status
There was no statistically significant association in the
T3 tertile and continuous analysis concerning tumours
with positive ER status (Tables 3 and 4). However, in
postmenopausal women, the association was statistically
significant both in the crude and adjusted analysis
(Table 5). T3 levels in the highest tertile were associated
with a high risk of tumours with a negative ER status
(Table 3). These statistically significant associations
remained in the continuous analysis and the analysis
restricted to menopausal women (Tables 4 and 5). Among
postmenopausal women, the association with ER negative
tumours (HR: 4.69) was clearly higher than the association
with ER positive tumours (2.48).PGR status
There was no statistically significant association in the
tertile and continuous analysis and positive PGR status
(Tables 3 and 4). There was however, a positive statistically
significant association among postmenopausal women
(Table 5). Concerning negative PGR status, there was a
statistically significant association in the highest tertile
(Table 3) and the association remained in the continuous
models (Tables 4 and 5). The highest HR in postmeno-
pausal women was seen in relation with PGR negative
tumours.Discussion
This is the first prospective study on serum T3 levels in
relation to prognostic factors in breast cancer. It shows a
positive association between higher serum concentra-
tions of T3 and presence of lymph node metastases and
negative ER and PGR status. The association of T3 with
these negative prognostic factors is also interesting in
comparison with our previous study [11], where there
was an association of T3 with an increase in mortality
from breast cancer. Although not fully comparable, these
findings indicate a possible common component.
This study was based on a cohort of middle-aged
women with a high participation rate (70%) [12], that is
30% did not take part therefore absolute risks may not
be applicable to all age groups or to the general popu-
lation. Due to a wide distribution of T3 levels, internal
comparisons were made and our estimates of relative
risks should not be affected by selection bias.
Table 2 Distribution of potential risk factors for breast cancer according to serum T3 level
Factor T3 quartile
1 2 3 All
n = 682 n = 765 n = 738 n = 2185
Column percent (T3 levels in italics)
T3 (mIU/l) <1.70 1.70-1.90 >1.90
Age
< 50 60.6 37.9 22.4 39.7
> 50 39.4 62.1 77.6 60.3
Education
<12 years 55.1 55.9 62.5 57.9
12 years 20.8 26.9 22.4 23.5
>12 years 19.6 13.5 11.2 14.6
Missing 4.4 3.7 3.9 4.0
Married 56.7 51.8 50.4 52.9
Missing 0.7 3.8 12.6 5.8
Smoking
Never 44.0 48.5 47.0 46.6
Current 35.3 33.3 33.3 34.0
Ex 20.7 18.0 18.8 19.1
Missing - 0.1 0.8 0.3
Alcohol consumption
Nothing 13.5 14.0 17.8 15.1
Less than every week 56.9 60.9 61.0 59.7
Every week 29.5 25.0 20.1 24.7
Missing 0.1 0.1 1.2 0.5
Menarche < 12 years 14.4 12.7 11.0 12.6
Missing 0.1 0.7 1.4 0.7
OC-use 4.5 7.1 11.1 7.6
Missing - 0.1 0.9 0.4
Nulliparity 17.4 15.4 18.6 17.1
Missing - 0.1 0.7 0.3
Peri/postmenopausal 41.2 63.3 75.5 60.5
HRT in peri/postmenopausal 13.9 13.8 17.6 15.4
Missing - - 0.2 0.1
Height
≤160 24.6 30.6 33.3 29.7
>160≤ 165 32.7 32.3 31.0 32.0
>165≤ 170 27.0 22.9 24.3 24.6
>170 15.7 14.2 11.4 13.7
BMI
<20 13.8 8.5 8.3 10.1
≥20 < 25 62.2 55.0 47.6 54.7
≥25 < 30 18.3 27.7 29.8 25.5
≥30 5.7 8.8 14.4 9.7
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Table 3 T3 tertiles and risk of specific prognostic factors in breast cancer
Tumour group Tertile* Cases HR HR** HR***
(n) (95% CI) (95% CI) (95% CI)
All Tertile 1 38 1.0 1.0 1.0
n = 149 Tertile 2 54 1.25 (0.85-1.84) 1.33 (0.90-1.97) 1.38 (0.93-2.04)
Tertile 3 57 1.34 (0.92-1.97) 1.50 (1.01-2.23) 1.61 (1.07-2.43)
Grade I Tertile 1 12 1.00 1.00 1.00
n = 42 Tertile 2 20 1.51 (0.74-3.09) 1.57 (0.76-3.26) 1.68 (0.81-3.49)
Tertile 3 10 0.79 (0.34-1.82) 0.84 (0.35-2.01) 0.97 (0.40-2.37)
Grade II Tertile 1 14 1.00 1.00 1.00
n = 56 Tertile 2 14 0.91 (0.43-1.19) 0.95 (0.45-2.01) 0.98 (0.46-2.69)
Tertile 3 28 1.89 (1.00-3.50) 2.04 (1.04-4.00) 2.13 (1.06-4.30)
Grade III Tertile 1 7 1.00 1.00 1.00
n = 38 Tertile 2 17 2.21 (0.92-5.32) 2.30 (0.94-5.61) 2.34 (0.96-5.74)
Tertile 3 14 1.90 (0.77-4.71) 2.04 (0.80-5.23) 2.14 (0.82-5.59)
Size ≤20 mm Tertile 1 28 1.00 1.00 1.00
n = 93 Tertile 2 31 1.01 (0.60-1.68) 1.04 (0.62-1.75) 1.09 (0.65-1.84)
Tertile 3 34 1.15 (0.70-1.89) 1.21 (0.72-2.05) 1.36 (0.79-2.33)
Size >20 mm Tertile 1 6 1.00 1.00 1.00
n = 45 Tertile 2 20 3.02 (1.21-7.53) 3.21 (1.28-8.07) 3.19 (1.26-8.06)
Tertile 3 19 3.01 (1.20-7.53) 3.33 (1.30-8.58) 3.17 (1.20-8.36)
Node positive Tertile 1 5 1.00 1.00 1.00
n = 39 Tertile 2 16 2.90 (1.06-7.92) 3.22 (1.17-8.87) 3.36 (1.22-9.30)
Tertile 3 18 3.40 (1.26-9.16) 4.08 (1.47-11.32) 4.53 (1.60-12.83)
Node negative Tertile 1 27 1.00 1.00 1.00
n = 91 Tertile 2 33 1.11 (0.67-1.85) 1.13 (0.67-1.89) 1.18 (0.70-1.99)
Tertile 3 31 1.08 (0.65-1.82) 1.12 (0.65-1.92) 1.20 (0.69-2.10)
ER positive Tertile 1 28 1.00 1.00 1.00
n = 105 Tertile 2 41 1.32 (0.82-2.15) 1.37 (0.84-2.23) 1.42 (0.87-2.32)
Tertile 3 36 1.22 (0.74-1.99) 1.28 (0.77-2.15) 1.39 (0.82-2.36)
ER negative Tertile 1 6 1.00 1.00 1.00
n = 36 Tertile 2 11 1.67 (0.62-4.52) 1.75 (0.64-4.77) 1.85 (0.68-5.09)
Tertile 3 19 3.01 (1.20-7.53) 3.24 (1.25-8.40) 3.52 (1.32-9.41)
PGR positive Tertile 1 27 1.00 1.00 1.00
n = 97 Tertile 2 36 1.21 (0.73-1.99) 1.25 (0.75-2.08) 1.27 (0.77-2.13)
Tertile 3 34 1.19 (0.72-1.97) 1.26 (0.74-2.14) 1.32 (0.77-2.27)
PGR negative Tertile 1 7 1.00 1.00 1.00
n = 44 Tertile 2 16 2.09 (0.86-5.07) 2.15 (0.87-5.29) 2.35 (0.96-5.80)
Tertile 3 21 2.87 (1.22-6.75) 3.03 (1.25-7.34) 3.52 (1.42-8.75)
*Cut-offs: tertile 1 (<1.70 ), tertile 2 (1.70-1.90 ), and tertile 3 (>1.9 ), **adjusted for age, ***adjusted for age and oral contraceptives.
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Death Registry have been validated and found to have a
completeness of about 99% [18], resulting in a very
complete follow up.
It is unlikely that women with T3 levels within the upper
limit of the normal range are more prone to participate in
mammography screening than others, hence a possibledetection bias in hyperthyroid breast cancer patients was
probably not present.
There is a well-known circadian variation concerning
T3 [19]. Ranking of individuals over time is, however,
quite stable [20]. A true variation over time would most
likely have led to an un-differential misclassification of
T3 and, hence, attenuated observed risks.
Table 4 Continuous T3 and risk of specific prognostic
factors in breast cancer
Tumour group HR (95% CI) HR*(95% CI) HR**(95% CI)
All 1.57 (1.06-2.32) 1.75 (1.18-2.60) 1.89 (1.27-2.82)
Grade I 0.93 (0.40-2.13) 1.00 (0.42-2.39) 1.20 (0.50-2.89)
Grade II 2.45 (1.32-4.55) 2.61 (1.40-4.87) 2.68 (1.42-5.06)
Grade III 1.68 (0.75-3.80) 1.78 (0.80-4.10) 1.86 (0.80-4.36)
Size ≤20 mm 1.53 (0.90-2.60) 1.65 (0.96-2.84) 1.88 (1.09-3.23)
Size >20 mm 1.98 (0.96-4.09) 2.11 (1.01-4.41) 1.96 (0.90-4.26)
Node positive 2.81 (1.39-5.67) 3.13 (1.57-6.23) 3.34 (1.70-6.56)
Node negative 1.18 (0.68-2.05) 1.22 (0.68-2.17) 1.32 (0.73-2.38)
ER positive 1.38 (0.83-2.28) 1.46 (0.87-2.46) 1.60 (0.95-2.71)
ER negative 3.95 (1.97-7.90) 4.15 (2.08-8.30) 4.32 (2.16-8.61)
PGR positive 1.38 (0.82-2.33) 1.48 (0.86-2.53) 1.57 (0.91-2.71)
PGR negative 3.38 (1.74-6.56) 3.53 (1.80-6.89) 3.89 (2.02-7.50)
RR *adjusted for age, RR **adjusted for age and oral contraceptives.
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an important methodological aspect. Most T3 in the
circulation is bound to three transport proteins, thyroxin
binding globulin (TBG), transthyretin and albumin. An
increased TBG concentration leads to higher levels of
total T3, and this is important to consider in studies of
breast cancer risk, as exogenous oestrogens, that are risk
factors for breast cancer, lead to increased TBG binding
capacity [21]. This was handled by a sensitivity analysis
were women treated with HRT and OC were excluded,
and by adjusting for these confounders in all the analyses.
The results after exclusion were very similar.
A limitation of the study is that in the baseline ques-
tionnaire used to collect data from the participants,
there were no questions on co-morbidities or medicationTable 5 Continuous T3 and risk of specific prognostic
factors in breast cancer in postmenopausal women
Tumour group RR (95% CI) RR* (95% CI) RR** (95% CI)
All 2.87 (1.86-4.43) 2.85 (1.86–4.37) 2.88 (1.90-4.37)
Grade I 2.32 (0.85-6.36) 2.35 (0.82-6.75) 2.37 (0.83-6.77)
Grade II 4.12 (2.19-7.77) 3.99 (2.17-7.36) 3.98 (2.19-7.23)
Grade III 1.18 (0.39-3.55) 1.24 (0.42-3.67) 1.30 (0.45-3.81)
Size ≤20 mm 3.28 (1.86-5.76) 3.31 (1.86-5.89) 3.33 (1.89-5.86)
Size >20 mm 1.64 (0.63-4.26) 1.76 (0.71-4.33) 1.83 (0.76-4.42)
Node positive 3.44 (1.54-7.66) 3.35 (1.59-7.07) 3.37 (1.63-6.96)
Node negative 2.08 (1.05-4.10) 2.08 (1.05-4.10) 2.12 (1.08-4.15)
ER positive 2.44 (1.38-4.32) 2.44 (1.39-4.29) 2.48 (1.43-4.31)
ER negative 4.83 (2.18-10.69) 4.72 (2.16-10.29) 4.69 (2.19-10.06)
PGR positive 2.59 (1.44-4.65) 2.59 (1.45-4.63) 2.62 (1.48-4.63)
PGR negative 3.87 (1.79-8.33) 3.79 (1.81-7.96) 3.81 (1.85-7.84)
RR *adjusted for age, RR **adjusted for age and oral contraceptives.which may affect thyroid function. Neither was there in-
formation on thyroxin use specifically. This was handled
by excluding women who affirmed any treatment for
goitre, which probably limited the interference of unre-
ported thyroxin use with the results in the present study.
The current study is the first prospective study to date
on T3 levels and prognostic factors in breast cancer and
therefore there is no expected strength of the associations.
Hence, we have not performed a priori power calculation.
In our study, the number of cases was quite limited leading
to wide confidence intervals and low statistical precision.
This led to an imprecision in the estimates related to T3,
and the lack of association between T3 and breast cancer
histological grade III could be due to a type II error.
Furthermore, statistical precision was an even more
serious problem in analyses stratified for menopausal
status, and these results, with very wide CI:s, should be
regarded with caution.
An additional problem related to the limited number
of breast cancer cases in the different subgroups was
that not all confounders could be included at the same
time in the final model for each respective endpoint.
However, only the factor included, namely OC, had a
substantial change off effect, 0.14. This indicates that
the lack of adjustment for all factors did not seriously
confound the observed HRs.
The potential association between thyroid hormones
and outcome following breast cancer has been discussed
for more than a century. Studies on the relation to breast
cancer aggressiveness have however been very scarce. We
found no prospective study on the association of T3 levels
and prognostic factors in breast cancer.
In a cross-sectional study, it has been shown that
thyroid autoimmunity in relation to breast cancer ag-
gressiveness is associated with a lower frequency of
distant metastasis [6]. Another cross-sectional study
on thyroid conditions and breast cancer aggressiveness
found no relation to the histopathological grade but
higher frequency of metastatic lymph nodes and vascu-
lar invasion in patients with thyroid pathology [7]. This
finding was in line with a recent experimental study
that showed an increased invasiveness and formation
of metastasis in breast cancer of hypothyroid mice
[22]. On the contrary, an early cross-sectional study by
Lemaire et al., showed no relation between thyroid
function and TNM stage of breast cancer [8]. A problem
in the interpretation of the above studies is that thyroid
hormones may indeed be affected by prevalent breast can-
cer, stress, or treatment. Breast cancer per se, as well as its
treatment, may affect hormonal levels. Such a condition,
confounding the results of cross sectional studies is the
non-thyroidal illness syndrome. This is a condition char-
acterised by abnormal thyroid function test results in
patients with acute or chronic systemic illnesses without
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of this syndrome include low serum levels of T3, with
normal or low levels of T4 and normal or low levels of
TSH [23]. We do not believe that non-thyroidal illness
syndrome was an obstacle in our study since women
with prevalent breast cancer and cancer diagnosed up
to two years following baseline were excluded. Further-
more, for the baseline examination, the women attended
the hospital from their homes without any assistance, it is
therefore unlikely that they were suffering from a serious
underlying disease when the samples were taken.
We found that T3 levels were positively associated
with invasive breast cancer in general, both in the tertile
and continuous analyses. As previously reported [9],
this association was also present after stratification for
menopause status. Interestingly, these findings are in
line with experimental studies that have shown that
thyroid hormones influence both normal breast cell
differentiation [24] and breast cancer cell proliferation
[25-28].
Nottingham grade is an independent determinant of
survival in breast cancer. When using NHG as the end-
point we found a statistically significant association with
T3 only in grade II. If this merely reflects a higher amount
of cases – and therefore a higher statistical power in this
group – or if it depends on certain tumour characteristics
being more common in grade II tumours remains an open
question at present.
There was a positive association between the third T3
tertile and large tumours (>20 mm), but not for small
tumours. The continuous analysis showed a similar, high,
risk for both small and large tumours, although only sta-
tistically significant for small tumours. In postmenopausal
women, there was a high risk of large tumours, but it was
not statistically significant and the risk for small tumours
was clearly higher. Taken together these findings suggest
that there may be an association between high thyroid
hormone levels and large tumours, but the even stronger
association with small tumours in postmenopausal women
is intriguing and together with the fact that CIs were gener-
ally wide, these findings need to be confirmed. Given the
overall association with large sized tumours this could be
explained by the proliferative effect of T3 on breast cancer
cell lines reported in experimental studies [24-27], but fur-
ther studies specifically on tumour size would be of value.
All analyses showed a positive association with presence
of lymph node metastases. In postmenopausal women
there was also a statistically significant association with
negative lymph node status. To clarify this finding, a
heterogeneity analysis was performed and showed to be
statistically significant for the point estimate in positive
lymph node status.
In the present study, there was an overall positive
association between serum T3 levels and ER negativebreast cancer. It has been shown that T3 binds and
stimulate ERs, acting in synergy with oestrogen on
breast cancer cell lines, potentiating the oestrogenic
effect and enhancing cell proliferation [28]. Our finding
implicates that T3 may also affect breast cancer by some
other mechanism(s) in addition to ER stimulation. An
interesting possibility involves the thyroid hormone
receptors (TR) α and β and their isoforms, which have
been demonstrated by various methods in breast cancer
cells [29,30]. Another observation of interest in this
context involves the HER2 gene, which is of fundamen-
tal importance in the current evaluation and treatment
of breast cancer. This gene is located close to the gene
for TRα on the long arm of chromosome 17, and ampli-
fication of the HER2 gene is often accompanied by co-
amplification of the gene for TRα [31]. In addition, point
mutations in breast cancer, that may affect tumour behav-
iour, have also been detected in the genes encoding TRα
and TRβ [32].
Further investigations in this field are called for, not
least considering the potential clinical implications for the
care of women with disorders or treatments resulting in
increased serum concentrations of T3. Judging from
recent observations in various types of malignant tumour
disease, this line of research may also lead to new strat-
egies for treatment of breast cancer [32,33].Conclusions
This prospective study of serum T3 levels in relation to
breast cancer aggressiveness is to our knowledge, the
first of its kind. We found statistically significant positive
associations between higher prediagnostic T3 levels and
occurrence of lymph node metastases, and negative ER
and PGR status. Furthermore, the association between
higher T3 levels and increased mortality in breast cancer,
as demonstrated by us previously, can be related to both
a higher incidence and more aggressive forms of breast
cancer.
Abbreviations
T3: Triiodothyronine; HR: Hazard ratio; ER: Oestrogen receptor; PGR: Progesterone
receptor; OC: Oral contraceptives; BMI: Body mass index; TSH: Thyroid
stimulating hormonr; RIA: Radioimmunoassay; NHG: Nottingham grade;
IHC: Immunohistochemical; LB: Lennart bondeson; CI: Confidence interval;
TBG: Thyroid binding globulin; HRT: Hormone replacement therapy;
TR: Thyroid receptor.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
AT and JM have made substantial contributions to conception and design of
the study and the analysis and interpretation of data. UBE and JM have
contributed to the acquisition of data. All authors have been involved in
drafting the manuscript and revising it critically for important intellectual
content. All authors read and approved the final manuscript.
Tosovic et al. BMC Cancer 2014, 14:536 Page 10 of 10
http://www.biomedcentral.com/1471-2407/14/536Acknowledgements
This work was supported by The Swedish Cancer Society, The Gunnar
Nilsson Cancer Foundation, The Ernhold Lundström Foundation, The Einar
and Inga Nilsson Foundation, The Malmö University Hospital Cancer
Research Fund, The Malmö University Hospital Funds and Donations, The
Crafoord Foundation, The Anna Lisa and Sven-Eric Lundgren.
Foundation, and the Mossfelt Foundation.
Author details
1Department of Surgery, Skåne University Hospital Malmö, Lund University,
Malmö, Sweden. 2Department of Pathology, University and Regional
Laboratories Region Skåne, Lund University, Malmö, Sweden. 3Department of
Endocrinology, Skåne University Hospital Malmö, Lund University, Malmö,
Sweden. 4Department of Reconstructive Surgery, Skåne University Hospital
Malmö, Lund University, Malmö, Sweden.
Received: 14 November 2013 Accepted: 14 July 2014
Published: 24 July 2014References
1. Sarlis NJ, Gourgiotis L, Pucino F, Tolis GJ: Lack of association between
Hashimoto thyroiditis and breast cancer: a quantitative research
synthesis. Hormones (Athens) 2002, 1:35–41.
2. Goldman MB: Thyroid diseases and breast cancer. Epidemiol Rev 1990,
12:16–28.
3. Smyth PP: The thyroid and breast cancer: a significant association? Ann
Med 1997, 29:189–191.
4. Fiore E, Giustarini E, Mammoli C, Fragomeni F, Campani D, Muller I, Pinchera
A, Giani C: Favourable predictive value of thyroid autoimmunity in high
aggressive breast cancer. J Endocrinol Invest 2007, 30:734–738.
5. Jiskra J, Barkmanova J, Limanova Z, La’nska V, Smutek D, Potlukova E,
Antosova M: Thyroid autoimmunity occurs more frequently in women
with breast cancer compared to women with colorectal cancer and
controls but it has no impact on relapse-free and overall survival. Oncol
Rep 2007, 18:1603–1611.
6. Farahati J, Roggenbuck D, Gilman E, Schütte M, Jagminaite E, Seyed Zakavi
R, Löning T, Heissen E: Anti-thyroid peroxidase antibodies are associated
with the absence of distant metastases in patients with newly
diagnosed breast cancer. Clin Chem Lab Med 2012, 50:709–714.
7. Cengiz O, Bozkurt B, Unal B, Yildirim O, Karabeyoglu M, Eroglu A, Kocer
B, Ulas M: The relationship between prognostic factors of breast
cancer and thyroid disorders in Turkish women. J Surg Oncol 2004,
87:19–25.
8. Lemaire M, Baugnet-Mahieu L: Thyroid function in women with breast
cancer. Eur J Cancer Clin Oncol 1986, 22:301–307.
9. Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J:
Prospectively measured triiodothyronine levels are positively associated
with breast cancer risk in postmenopausal women. Breast Cancer Res
2010, 12:R33.
10. Tosovic A, Bondenson AG, Bondeson L, Ericsson UB, Malm J, Manjer J:
Prospectively measured thyroid hormones and thyroid peroxidase
antibodies in relation to breast cancer risk. Int J Cancer 2012,
131:2126–2133.
11. Tosovic A, Bondenson AG, Bondeson L, Ericsson UB, Manjer J:
Triiodothyronine levels in relation to mortality from breast cancer and all
causes: a population-based prospective cohort study. Eur J Endocrinol
2013, 168:483–490.
12. Manjer J, Berglund G, Bondesson L, Garne JP, Janzon L, Malina J: Breast
cancer incidence in relation to smoking cessation. Breast Cancer Res Treat
2000, 61:121–129.
13. Thorell JL, Larson SM: Radioimmunoassay and related techniques.
Methodology and Clinical Applications Saint Louis: Mosby; 1978.
14. Almquist M, Anagnostaki L, Bondeson L, Bondeson AG, Borgquist S,
Landberg G, Malina J, Malm J, Manjer J: Serum calcium and tumour
aggressiveness in breast cancer. Eur J Cancer Prev 2009, 18:354–360.
15. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The
value of histological grade in breast cancer: experience from a large
study with long-term follow-up. Histopathology 1991, 19:403–410.
16. Michael B, Harvey S: Fast Facts – Breast Cancer. Oxford: Health Press
Limited; 2002.17. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L: Smoking
associated with hormone receptor negative breast cancer. Int J Cancer
2001, 91:580–584.
18. Garne JP: Invasive breast cancer in Malmo 1961-1992 – an epidemiological
study. In A PhD Thesis. Lund, Sweden: Department of Surgery, Lund
University; 1996.
19. Russell W, Harrison RF, Smith N, Darzy K, Shalet S, Weetman AP, Ross RJ:
Free triiodothyronine has a distinct circadian rhythm that is delayed but
parallels thyrotropin levels. J Clin Endocrinol Metab 2008, 93:2300–2306.
20. Andersen S, Pedersen KM, Bruun NH, Laurberg P: Narrow individual
variations in serum T(4) and T(3) in normal subjects: a clue to the
understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002,
87:1068–1072.
21. Utiger RD: Estrogen, thyroxine binding in serum, and thyroxine therapy.
N Engl J Med 2001, 344:1784.
22. Martínez-Iglesias O, García-Silva S, Regadera J, Aranda A: Hypothyroidism
Enhances Tumour Invasiveness and Metastasis Development. PLoS One
2009, 4:e6428.
23. Economidou F, Douka E, Tzanela M, Nanas S, Kotanidou A: Thyroid function
during critical illness. Hormones 2011, 10:117–124.
24. Saraiva PP, Figueiredo NB, Padovani CR, Bretani MM, Nogueira CR: Profile of
thyroid hormones in breast cancer patients. Braz J Med Biol Res 2005,
38:761–765.
25. Dinda S, Sanchez A, Moudgil V: Estrogen-like effects of thyroid hormone
on the regulation of tumor suppressor proteins, p53 and retinoblastoma,
in breast cancer cells. Oncogene 2002, 21:761–768.
26. Conde I, Paniagua R, Zamora J, Blanquez MJ, Fraile B, Ruiz A, Arenas MI:
Influence of thyroid hormone receptors on breast cancer cell
proliferation. Ann Oncol 2006, 17:60–64.
27. Nogueira CR, Brentani MM: Triiodothyronine mimics the effects of
estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol 1996,
59:271–279.
28. Hall LC, Salazar EP, Kane SR, Liu N: Effects of thyroid hormones on human
breast cancer cell proliferation. J Steroid Biochem Mol Biol 2008, 109:57–66.
29. Silva JM, Dominguez G, González-Sancho JM, Garcia JM, Silva J, Garcia-Andrade
C, Navarro A, Muñoz A, Bonilla F: Expression of thyroid hormone
receptor/erbA genes is altered in human breast cancer. Oncogene
2002, 21:4307–4316.
30. Ditsch N, Toth B, Himsl I, Lenhard M, Ochsenkühn R, Friese K, Mayr D,
Jeschke U: Thyroid hormone receptor (TR)alpha and TRbeta expression in
breast cancer. Histol Histopathol 2013, 28:227–237.
31. van de Vijver M vBR, Devilee P, Cornelisse C, Peterse J, Nusse R:
Amplification of the neu(c-erbB-2) oncogene in human mammary
tumors is relatively frequent and is often acccompanied by amplification
of the linked c-erbA oncogene. Mol Cell Biol 1987, 7:2019–2023.
32. Moeller LC, Führer D: Thyroid hormones, thyroid hormone receptors, and
cancer: a clinical perspective. Endocr Relat Cancer 2013, 20:R19–R29.
33. Huang JBJG, Xing L, Jin LB, Xu CB, Xiong X, Li HY, Ren GS, Wu KN, Kong LQ:
Implication from thyroid function decreasing during chemotherapy in
breast cancer patients: chemosensitization role of triiodothyronine. BMC
Cancer 2013, 13:334.
doi:10.1186/1471-2407-14-536
Cite this article as: Tosovic et al.: T3 levels in relation to prognostic
factors in breast cancer: a population-based prospective cohort study.
BMC Cancer 2014 14:536.
